Artisan Pharma closes $39 million series A financing

By Elaine Rigoli

Tampa, Fla., Sept. 6 - Artisan Pharma, Inc. said it secured $39 million through a series A financing round led by NGN Capital LLC in a syndicate with Jafco, New Leaf Venture Partners, Bio*One Capital and NovaQuest (Quintiles).

Artisan said its mission is to in-license clinical-stage products for development and commercialization in critical-care and hospital-based markets.

As part of the financing, Asahi Kasei Pharma Corp. has licensed a late-stage clinical development biologic, ART-123, to Artisan. The license includes development and commercialization rights to all pharmaceutical applications worldwide except for Japan, China, Taiwan and Korea, where Asahi retains all rights.

Artisan Pharma is a biopharmaceutical company based in Framingham, Mass.

Issuer: Artisan Pharma, Inc.

Issue: Series A financing

Amount: $39 million

Investors: NGN Capital LLC, Jafco, New Leaf Venture Partners, Bio*One Capital and NovaQuest (Quintiles).

Announcement date: Sept. 6

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.